ImmunoCellular Therapeutics Stock Forecast, Price & News

+0.13 (+35.14 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $0.50
50-Day Range
MA: $0.63
52-Week Range
Now: $0.50
Volume4,698 shs
Average Volume6,605 shs
Market Capitalization$2.10 million
P/E RatioN/A
Dividend YieldN/A
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 30, 2006 and is headquartered in Calabasas, CA.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Phone(818) 264-2300
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$2.10 million
Next Earnings DateN/A
OptionableNot Optionable


No headlines for this company have been tracked by MarketBeat.com


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1912th out of 2,010 stocks

Pharmaceutical Preparations Industry

749th out of 769 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.13 (+35.14 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMUCD News and Ratings via Email

Sign-up to receive the latest news and ratings for IMUCD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ImmunoCellular Therapeutics (OTCMKTS:IMUCD) Frequently Asked Questions

What stocks does MarketBeat like better than ImmunoCellular Therapeutics?

Wall Street analysts have given ImmunoCellular Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ImmunoCellular Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are ImmunoCellular Therapeutics' key executives?

ImmunoCellular Therapeutics' management team includes the following people:
  • Mr. Gary S. Titus CPA, Independent Chairman & Corp. Sec. (Age 60, Pay $63k)
  • Mr. Sanford J. Hillsberg, Co-Founder (Age 71)
  • Dr. John S. Yu, Founder & Director (Age 56)

Who are some of ImmunoCellular Therapeutics' key competitors?

What is ImmunoCellular Therapeutics' stock symbol?

ImmunoCellular Therapeutics trades on the OTCMKTS under the ticker symbol "IMUCD."

How do I buy shares of ImmunoCellular Therapeutics?

Shares of IMUCD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoCellular Therapeutics' stock price today?

One share of IMUCD stock can currently be purchased for approximately $0.50.

How much money does ImmunoCellular Therapeutics make?

ImmunoCellular Therapeutics has a market capitalization of $2.10 million.

How many employees does ImmunoCellular Therapeutics have?

ImmunoCellular Therapeutics employs 3 workers across the globe.

What is ImmunoCellular Therapeutics' official website?

The official website for ImmunoCellular Therapeutics is www.imuc.com.

How can I contact ImmunoCellular Therapeutics?

The company can be reached via phone at (818) 264-2300.

This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.